J Nucl Cardiol by Arai, Andrew E.
The cardiac magnetic resonance (CMR) approach to assessing
myocardial viability
Andrew E. Arai, MD
Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, National
Institutes of Health, Department of Health and Human Services, Bethesda, MD
Abstract
Cardiac magnetic resonance (CMR) is a noninvasive imaging method that can determine
myocardial anatomy, function, perfusion, and viability in a relative short examination. In terms of
viability assessment, CMR can determine viability in a non-contrast enhanced scan using
dobutamine stress following protocols comparable to those developed for dobutamine
echocardiography. CMR can also determine viability with late gadolinium enhancement (LGE)
methods. The gadolinium-based contrast agents used for LGE differentiate viable myocardium
from scar on the basis of differences in cell membrane integrity for acute myocardial infarction. In
chronic myocardial infarction, the scarred tissue enhances much more than normal myocardium
due to increases in extracellular volume. LGE is well validated in pre-clinical and clinical studies
that now span from almost a cellular level in animals to human validations in a large international
multicenter clinical trial. Beyond infarct size or infarct detection, LGE is a strong predictor of
mortality and adverse cardiac events. CMR can also image microvascular obstruction and
intracardiac thrombus. When combined with a measure of area at risk like T2-weighted images,
CMR can determine infarct size, area at risk, and thus estimate myocardial salvage 1–7 days after
acute myocardial infarction. Thus, CMR is a well validated technique that can assess viability by
gadolinium-free dobutamine stress testing or late gadolinium enhancement.
INTRODUCTION
A number of methods are now clinically available for assessing myocardial viability and
there is overlap in the pathophysiological mechanisms that enable each of these diagnostic
findings (Figure 1). Single photon emission computed tomography (SPECT) detects
viability by imaging a combination of myocardial metabolism and
perfusion. 201Thallium, 99mTc-sestamibi, and 99mTc-tetrofosmin are SPECT radiotracers
that can be used to assess viability. 18F-fluorodeoxyglucose combined with a perfusion
agent such as 13N-ammonia can assess metabolism, perfusion, and viability by positron
emission tomography (PET). Dobutamine stress echocardiography and dobutamine stress
MRI detect viability of dysfunctional myocardium on the basis of augmentation of
contractility or a biphasic response to low and higher dose dobutamine. Echocardiographic
bubble contrast agents represent a relatively pure intravascular perfusion assessment so do
not assess myocardial viability or cell membrane integrity per se. Catheter-based
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endocardial electrocardiogram mapping can detect viability and some of the initial
descriptions of inotropic reserve came from invasive ventriculography.
Cardiac magnetic resonance imaging (CMR) can characterize viability using low-dose
dobutamine stress and CMR can also determine viability with late gadolinium enhancement
(LGE). Iodinated contrast agents can delineate infarcted myocardium by x-ray computed
tomography (CT) in ways that are analogous to LGE imaging. Gadolinium and iodinated
contrast agents enhance fibrotic tissue by similar mechanisms since they distribute
throughout the interstitial space. Thus, all of the major cardiac imaging methods can be used
to determine myocardial viability. Considering the readership of this journal, the purpose of
this review will be to focus on how CMR can be used to image myocardial viability.
LOW-DOSE DOBUTAMINE STRESS MRI TO ASSESS MYOCARDIAL
VIABILITY
Although many physicians think about gadolinium enhanced CMR as a method for
assessing viability, dobutamine stress CMR was the first validated method. The very
concept of hibernating myocardium originated in the early days of bypass surgery when it
was noticed that some patients with left ventricular dysfunction had substantial improvement
of left ventricular function after revascularization.1,2 The concept of hibernating
myocardium was crystallized out of this observation of reversible, ischemic left ventricular
dysfunction.3 Many aspects of the pathophysiology of hibernating myocardium were
described by 1986 and recovery of global or regional function became a central tenet in the
entity.4 The concept that hibernating myocardium showed a “biphasic response”
characterized by an improvement in regional function during low-dose dobutamine infusions
but ischemic deterioration at high doses of dobutamine.5 This biphasic response has become
an important refinement in the non-invasive diagnosis of the hibernating myocardium.
Dobutamine stress CMR is performed following doses and imaging protocols that are
comparable to dobutamine stress echocardiography.6 After baseline imaging, graded doses
of dobutamine are infused and left ventricular function is imaged at each stage. A low-dose
dobutamine stress test typically looks for improvement of regional wall motion
abnormalities with a submaximal dose of the catecholamine. Some groups use low and high
doses of dobutamine to have the specificity of the biphasic response as an indicator of
hibernating myocardium. Most clinicians would use either type of response as a sign of
viability to maximize sensitivity of the test.
Dobutamine stress CMR is accurate for detecting significant coronary artery stenosis7–9 and
for characterizing hibernating myocardium. Baer et al published a series of studies exploring
the feasibility and accuracy of dobutamine stress CMR as a non-invasive test of myocardial
viability. In comparisons of dobutamine stress CMR and 18F-deoxyglucose PET,
dobutamine induced wall thickening was a better predictor of residual metabolic activity
than end diastolic wall thickness but grading a segment as viable if at least one of both CMR
parameters fulfilled viability criteria improved the sensitivity of CMR to 88% for 18F-
deoxyglucose PET assessed metabolic activity without adversely affecting specificity (87%)
or positive predictive accuracy (92%).10 Dobutamine stress CMR and dobutamine stress
echocardiography had similar diagnostic accuracy for viable myocardium relative to 18F-
deoxyglucose PET.11 Dobutamine stress CMR predicted recovery of function after
revascularization in patients with chronic regional wall motion abnormalities.12 In a head-to-
head comparison of dobutamine stress transesophageal echocardiography and dobutamine
stress CMR for predicting functional recovery of hibernating myocardium with a reference
standard that included successful revascularization of the ischemic territory, both tests were
highly accurate.13
Arai Page 2










Thus, dobutamine stress CMR can be used to characterize the likelihood of functional
recovery of regional wall motion abnormalities in patients with ischemic heart disease. One
particular advantage of this method is that gadolinium contrast is not needed so the method
can be used in patients with severe kidney disease. There is some evidence that dobutamine
stress MRI is a better predictor of functional recovery than late gadolinium enhancement
(LGE).14 The discrepancies in predicting recovery of function may represent analogous
differences between dobutamine echo and SPECT mechanisms of assessing viability as
described by Arrighi and Dilsizian.15 The use of regional wall thickening as the reference
standard for assessing viability may also introduce a bias favoring dobutamine wall motion
tests to assess viability. Not withstanding of these issues, dobutamine is a powerful method
for enabling viability assessment by CMR.
PATHOPHYSIOLOGICAL BASIS OF LATE GADOLINIUM ENHANCEMENT
Late gadolinium enhancement has become the most widely used way of assessing viability
by MRI. It has been known since 1984 that gadolinium enhances infarcted myocardium.16
However, it took a new generation of imaging methods17 and extensive validations to prove
that LGE accurately depicts myocardial infarction.
There are important temporal aspects of gadolinium enhancement of the heart that led to the
descriptive title late gadolinium enhancement (LGE). Simplistically, one can dissect the time
after a bolus injection of gadolinium into three physiologically distinct time periods (Figure
2). First pass perfusion occurs within about 20 seconds of the arrival of the contrast in the
heart after an intravenous injection. Perfusion can be quantified from images obtained in this
earliest time period.18 Early gadolinium enhancement (EGE) represents a period between
about 1 minute and 8 minutes after injection of gadolinium. Images obtained in the EGE
time period are still sensitive to severe perfusion defects such as microvascular obstruction
after acute myocardial infarction.
The exact timing of what qualifies for late gadolinium enhancement is still being defined but
most clinicians in 2011 have considered the time period between about 8 and 30 minutes
after injection of contrast a suitable time period for LGE imaging. The key requirement is
that the distribution of gadolinium into the interstitial space and blood volume are in a
reasonable approximation of a steady state. Factors such as microvascular obstruction delay
arrival of contrast and can leave dark patches within the core of an infarct that persist for
more than 10 minutes and thus strictly speaking violate this principle but practically can
simply be interpreted as a part of the infarct despite a lower signal intensity than the rest of
the infarct.
In general, late gadolinium enhancement is imaged with a technique called inversion
recovery. The result is an image where the technologist has adjusted the scan parameters in a
way to null the normal myocardium which means the normal myocardium appears
uniformly dark. Under such conditions, the infarct is brighter than normal myocardium and
readily visible (Figures 2, 3).
The distribution of gadolinium-based contrast in tissue defines viability and fibrosis (Figure
3). Since most of the gadolinium-based contrast agents approved by the Food and Drug
Administration are classified as extracellular agents, they rapidly enter the interstitial space
after an intravenous injection but are excluded from the intracellular space by the cell
membrane. Thus, gadolinium enhances normal myocardium slightly based on the size of the
extracellular volume fraction which is about 25% of the tissue. Acutely infarcted
myocardium enhances to a greater extent than normal myocardium since ruptured cell
membranes allow gadolinium into the intracellular space of infarcted cardiomyocytes.
Chronically infarcted myocardium enhances collagenous scar since that tissue has a
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relatively small intracellular space and large effective extracellular volume fraction (Figure
4).
VALIDATION OF LATE GADOLINIUM ENHANCEMENT AND COMPARISONS
TO SPECT OR PET
The spatial extent and localization of late gadolinium enhancement corresponds closely to
the location of infarcted myocardium as determined by triphenol tetrazolium chloride (TTC)
histopathology.19 Importantly, the correlations between LGE and TTC were strong and
showed almost no bias on day 1, day 3 and at 8 weeks after acute myocardial infarction in a
canine model. Electron probe x-ray microanalysis showed at about a mm scale that
gadolinium concentration was high in infarcted myocardium and much lower in normal
myocardium.20 Furthermore, careful analysis of LGE images showed that gadolinium was
elevated primarily in the infarct and not in the area at risk or remote myocardium.21 The
spatial correlation between gadolinium enhancement and fibrosis has now been validated
almost to a cellular level.22
The high resolution of late gadolinium enhancement translates to increased sensitivity for
detection and diagnosis of infarction. For example, CMR allows detection of microinfarcts
associated with side branch occlusion and embolization down stream from percutaneous
interventions in patients with elevated biomarkers.23,24 Infarcts that small were not
previously detectable in patients. CMR is more sensitive to subendocardial infarcts than
SPECT in head-to-head studies of animal models and in people.25 In patients with acute
myocardial infarction, infarct size as measured by CMR and SPECT correlated but SPECT
had 80% sensitivity compared to CMR which had a sensitivity of 100%.26 SPECT missed a
significant percent of infarcts in a right coronary or circumflex coronary artery
distribution,26,27 a problem potentially related to lack of attenuation correction. Similarly
PET and CMR measures of infarct size also correlate but Klein et al concluded that PET did
not detect 55% of segments with subendocardial infarcts. CMR can also detect right
ventricular infarction.28 In practical experience, many patients with small infarcts may go
undetected or described as a false positive biomarker study if studied with low resolution
techniques while in fact the patient actually has minimal coronary artery disease and simply
a very small myocardial infarction. Late gadolinium enhancement imaging has now been
validated at the multicenter clinical trial level.29
PREDICTING RECOVERY OF HIBERNATING MYOCARDIUM AFTER
REVASCULARIZATION
Clinical validation studies confirm that LGE images can determine myocardial viability and
predict recovery of function after revascularization. The first clinical study showed that the
transmural extent of infarction predicted the likelihood of functional recovery after
revascularization.30 That study was strong evidence that the increased resolution of MRI
viability assessment had unique clinical impact at that time. The study results were
confirmed by Selvanayagam et al.31 Late gadolinium enhancement can also predict recovery
of function downstream from chronic total occlusions.32
Thus, the transmural extent of late gadolinium enhancement is an index of viability in the
setting of chronic ischemic heart disease. At the same time, the graded relationship between
transmural extent of infarction and functional recovery means that it is difficult to predict
what will happen to segments with intermediate extent of infarction. In those situations, one
might consider a low dose dobutamine study to better clarify the likelihood of functional
recovery. Since perfusion, function, and viability can be imaged in a single CMR
examination, it may be helpful to use rest perfusion imaging to help determine whether
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hibernating myocardium is supplied by severely stenotic artery.33 One should recognize that
abnormal rest perfusion findings can be relatively subtle and may require careful
quantitative analysis to detect.
Realistically, the patient with clinically relevant questions regarding viability often
undergoes multimodality testing. In cases where FDG PET and CMR late gadolinium
enhancement have been performed, it may be useful to fuse these images for diagnostic
purposes. Both FDG and late gadolinium enhancement are highly sensitive tests—FDG for
residual viability and late gadolinium enhancement for scar. The combination of FDG and
late gadolinium enhancement may identify viable myocardium near or adjacent to scar.
VALIDATION OF LATE GADOLINIUM ENHANCEMENT IN THE SETTING OF
ACUTE MYOCARDIAL INFARCTION
Late gadolinium enhancement has also been validated in the setting of acute myocardial
infarction. Infarct size correlated with biomarkers and predicted recovery of function in
patients imaged 1–7 days after the acute event.34–37 Late gadolinium enhancement is a
better predictor of functional recovery after acute MI than CMR perfusion images.36,38 The
multi-center clinical trial included 282 patients studied within 16 days of acute myocardial
infarction.29 The sensitivity for detecting acute myocardial infarction was 99% at the highest
dose of gadoversetamide (0.3 mmol/kg). The accuracy for determining infarct related artery,
as determined by coronary angiography, was also 99% at the highest dose studied. Beyond
detection of infarction and infarct sizing, early gadolinium enhancement can detect
microvascular obstruction. Coupled with a CMR measure of area at risk, late gadolinium
enhancement after acute myocardial infarction can allow determination myocardial salvage.
These later two applications are discussed in later portions of this manuscript.
PROGNOSIS OF SCAR/FIBROSIS IMAGING
Several papers have shown that late gadolinium enhancement of the myocardium is
associated with adverse clinical outcomes. Kwong et al39 found that late gadolinium
enhancement found in patients without know myocardial infarction had incremental
prognostic value beyond clinical predictors, angiographically significant coronary stenosis,
and left ventricular size or function. Roes et al40 also found that late gadolinium
enhancement discriminated outcomes better than left ventricular size or ejection fraction.
Silent myocardial infarctions in diabetic subjects are associated with adverse events and
increased mortality.41 Other portions of the CMR exam provide additional prognostic value
beyond late gadolinium enhancement such as the presence of reversible perfusion defects.
Overall, late gadolinium enhancement, as a noninvasive image of myocardial scar or infarct,
is a strong predictor of mortality and adverse outcomes.
OTHER CLINICALLY RELEVANT FINDINGS BY GADOLINIUM
ENHANCEMENT
Beyond detecting infarction, gadolinium enhanced CMR turns out to be useful for a wide
range of other conditions. For example, CMR is sensitive (88%) and highly specific (99%)
for detecting intracardiac thrombus in a retrospective study of 361 patients with surgical or
pathological confirmation of the presence or absence of left ventricular thrombus.42 In that
study, trans-esophageal echocardiography had a sensitivity of 40% and transthoracic
echocardiography had a sensitivity of 27% while both ultrasound methods had a specificity
of 96%. In particular, laminated thrombus in the atria or in left ventricular wall motion
abnormalities are easier to detect on gadolinium enhanced CMR than other methods.43
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Microvascular obstruction is frequently observed after acute myocardial infarction and has
prognostic significance. Microvascular obstruction represents a residual myocardial
perfusion abnormality despite an open epicardial coronary artery. In many respects,
microvascular obstruction represents a severe injury. An early report by Wu et al44 found
that the presence of microvascular obstruction, as detected by CMR perfusion images,
portended poor prognosis in survivors of acute myocardial infarction. Other studies also
confirm the adverse prognostic significance of microvascular obstruction even though it may
represent a very small percent of the left ventricular myocardium.45 It seems that
microvascular obstruction is a marker of more severe injury since it appears associated with
longer ischemic times than even extensive late gadolinium enhancement.46 Considering
microvascular obstruction is relatively easy to image by CMR, this assessment should be
considered a standard part of viability assessment in patients with acute myocardial
infarction.
CMR can now determine ischemic area at risk and infarct size in a single examination 1–7
days after acute myocardial infarction. The difference between these measures allows
determination of myocardial salvage. T2-weighted CMR helps visualize the area at risk as a
hyperintense portion of myocardium relative to normal myocardium.47 This zone represents
myocardial edema which starts to form during the coronary occlusion.48 The T2 abnormality
is also present in non-reperfused infarcts.49 T2-weighted CMR can differentiate acute from
chronic myocardial infarction.50 The T2 abnormality corresponds to the area at risk in
patients51 and correlates with SPECT estimates of area at risk.52 The CMR estimates of area
at risk also correlate with coronary angiographic estimates of area at risk and the measured
myocardial salvage appropriately varies with time to reperfusion and TIMI flow post-
intervention.53
Much is still to be learned about the prognostic value of late gadolinium enhancement. For
example, a larger than median sized gadolinium enhanced border zone around infarcts is
associated with increased mortality.54 The morphology of the scar may also be a predictor of
arrhythmia risk.55
ADVANTAGES AND DISADVANTAGES OF USING MRI TO ASSESS
MYOCARDIAL VIABILITY
Despite the many advantages of using MRI to assess viability, there are also a number of
disadvantages to the technology consider (Table 1). Although there is now one pacemaker is
deemed conditionally safe for MRI by the Food and Drug Administration (FDA) that
approval does not extend to the chest. Similarly, gadolinium-based contrast agents are not
approved by the FDA for the heart as of mid-2011. Gadolinium is relatively contraindicated
in patients with severe kidney disease due to the risk of developing nephrogenic systemic
fibrosis. In patients that cannot receive gadolinium, dobutamine stress CMR should be
considered. MRI is an expensive technology but this is partially mitigated by the fact that
alternative methods for assessing viability are also expensive. Obesity and claustrophobia
can limit which patients can be studied by MRI. In addition, arrhythmias can reduce image
quality since the best CMR images are formed by combining several different heart beats
into one better quality image. Nonetheless, there are real-time imaging methods that are
good enough to characterize infarct size and detect intracardiac thrombus missed by
echocardiography (see supplementary online case).
In summary, CMR is a powerful technique for assessing viability. The strengths of the
technique relate to the high resolution and quality information that can be obtained. The
ability assess function, perfusion, viability, and intracardiac thrombus is a highly useful set
of clinical data. The technique depends on magnetic fields and radiofrequency transmissions
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so do not involve ionizing radiation. The viability methods have now been validated from
almost a cellular level up through multicenter clinical trials. Furthermore, CMR is now able
to routinely assess microvascular obstruction and area at risk so is a particularly promising
modality for assessment of viability early after acute myocardial infarction.
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Methods available for assessing myocardial viability.
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Temporal aspects of late gadolinium enhancement.
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The volume of distribution or extracellular volume fraction differentiates normal
myocardium from acutely infarcted myocardium and chronically infarcted or fibrotic
myocardium. See text for more detailed description.
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Late gadolinium enhancement defines viability and fibrosis at nearly a cellular resolution.
Permission to reproduce this figure was approved by circulation cardiovascular imaging22.
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Advantages and disadvantages of using MRI to assess myocardial viability
Advantages Disadvantages
High quality and high resolution assessment of viability Contraindications include pacemakers, defibrillators, and many other
devices
Multidimensional exam (function, perfusion, viability, thrombus) Gadolinium is relatively contraindicated for eGFR <30 mL/min/1.73
BSA
Gadolinium no stress option vs dobutamine Expensive
No ionizing radiation Obesity
Validated from a cellular level up to multicenter trials Arrhythmias
Can assess viability, area at risk, and myocardial salvage after acute MI Claustrophobia
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